To study the efficacy of Niconrandil drug as an add-on treatment to the standard care given to the patient with acute ischemic stroke

Not Applicable

Completed

• Conditions: Health Condition 1: G94- Other disorders of brain in diseases classified elsewhere

• Registration Number: CTRI/2022/01/039227
• Lead Sponsor: SRMIST

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2023-04-14
• Last Update Posted: 18 September 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 19

Inclusion Criteria

Age 18 -75 years.

-Both genders.

-Diagnosis of acute ischemic stroke.

-More than 24 hours of onset of symptoms and not greater than 96 hours.

-Modified Rankin scale greater than two.

-Ability to ingest oral medication.

-BMI >18.5 kg /m².

Exclusion Criteria

Haemorrhagic stroke.

Hypotension with a SBP < 100 mmHg.

Patients on ACEIs and ARBs.

Patients on steroids.

Patients with respiratory compromise.

Patients on antidepressant drugs.

Severe acid peptic disease.

Kidney dysfunction (GFR < 30ml /min).

Intake of NSAID (exemption of Paracetamol).

Severe unstable medical illnesses, including uncontrolled cardiac conditions or heart failure, cardiogenic shock (New York Heart Association Class III or IV).

Use of any investigational agents within 30 days prior to screening.

Pregnant women and lactating mothers.

Severe hypovolemia.

Severe liver dysfunction.

Severe bradycardia ( <50 bpm).

Patients with G6PD deficiency.

Clotting factor Deficiency

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Modified Rankin Scale <br/ ><br>Timepoint: 0, 30 and 90 days

Secondary Outcome Measures

Name	Time	Method
Barthel indexTimepoint: 0, 30 and 90 days